Scientific and technological prospection on the use of Cannabis sativa (Hemp) in neuropathic patients or with neuropsychiatric disorders
DOI:
https://doi.org/10.33448/rsd-v12i2.36990Keywords:
Cannabis sativa; Phytocannabinoids; Treatment.Abstract
Neurodegenerative diseases and/or disorders, as well as pediatric neuropathies and neuropsychiatric disorders are multicausal and have in common the direct or indirect impact on the performance of activities of daily living, whether for psychological, social or economic reasons for the individual and family. The current treatments available are generally pharmacological for symptom control and progression delay, not encompassing disease regression or prevention. Due to the need for new therapeutic approaches in recent years, there has been an increase in the number of studies involving herbal medicines derived from plants with anti-inflammatory and antioxidant bioactive potential, which provides alternative and economic methods for the population. Among plants with therapeutic potential, Cannabis sativa has become the focus of research because it has more than 560 constituents with therapeutic potential for the treatment and relief of symptoms in serious diseases, such as CBD and THC cannabinoids. This potential can be explained by its ability to interact with the cannabinoid system, an important regulator of physiological processes in the human body, composed of eCBs, AEA and 2-AG that couple to CB1 and CB2 receptors present in the CNS and PNS. These receptors are G protein-coupled, therefore C. sativa cannabinoids have the potential to interact with G protein receptors, being able to interact with neurotransmitters and neuromodulators involved in psychomotor coordination, memory, mood and pain. In view of the above, the present study aimed to collect and analyze qualitative and quantitative data for the analysis of Cannabis sativa in therapeutics against neuropathologies, neuropsychiatric disorders and neurodegenerative diseases. The present study is an exploratory and qualitative-quantitative research carried out through a survey of data for scientific and technological prospection during the period from October 20, 2021 to July 20, 2022. To search for articles PubMed and ScienceDirect databases were used. Meanwhile, the EPO, WIPO and INPI databases were used for patent searches. The analysis continued with the identification of relevant publications based on the presence of keywords in the title or abstract. As a result, the qualitative-quantitative study exposed a low number of patents and articles related to the subject, which may be justified due to the use of opioids as a mechanism of medicinal treatment still being a target of studies, despite having millenary records of the use of this plant in specific for medicinal purposes in Asia, which highlights the importance of developing new studies to evaluate in vitro and in vivo the agonist activity of the compounds exposed above. Therefore, it is possible to conclude, given the above, that phytocannabinoids have potential for the treatment of neuropathies, neuropsychiatric disorders and neurodegenerative diseases.
References
Amparo, K. K. D. S, Ribeiro, M. D. C. O, & Guarieiro, L. L. N. (2012). Estudo de caso utilizando mapeamento de prospecção tecnológica como principal ferramenta de busca científica. Perspectivas em Ciência da Informação. 17, 195-209.
Bonini, A. S. et al. (2018). Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol. 227, 300-315.
Científico, C, Vasconcelos, M. M. & Oliveira N. F. (2019). Indicações para uso da Cannabis em pacientes pediátricos: uma revisão baseada em evidências.
Checkoway, H, Lundin, J. I, & Kelada, S. N. (2011). Neurodegenerative diseases. IARC Sci Publ. 163, 407-19.
Chetia, S, & Borah, G. (2020). Δ 9-Tetrahydrocannabinol Toxicity and Validation of Cannabidiol on Brain Dopamine Levels: An Assessment on Cannabis Duplicity. Nat Prod Bioprospect. 10(5), 285-296.
Doughty, C. T. et al. (2019). Entrapment Neuropathies of the Upper Extremity. Med Clin North Am. 103(2), 357-370.
Dugger, B. N, & Dickson, D. W. (2017). Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 9(7), a028035.
Ebbert, J. O, Sharp, E. L, & Hurt, R. T. (2018). Medical Cannabis. Mayo Clin Proc. 93(12), 1842-1847.
Elsohly, M. A. et al. (2017). Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod. 103, 1-36.
Erkkinen, M. G, Kim, M. O, & Geschwind, M. D. (2018). Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 10(4), a033118.
Fries, G. R. (2019). Genética e epigenética como ferramentas para informar a fisiopatologia dos transtornos neuropsiquiátricos. Rev Bras Psiquiatria. 41(1).
Gwathmey, K. G. et al. (2020). Nutritional neuropathies. Muscle Nerve. 62(1), 13-29.
Godoy-Matos, AF. et al. The endocannabinoid system: a new paradigma in the metabolic syndrome treatment. Arq Bras Endocrinol Metab. 50(2), 2006.
Hanewinckel, R. et al. (2016). Peripheral neuropathies. Handb Clin Nerol. 138, 263-82.
Kovacs, G G. (2017). Concepts and classification of neurodegenerative diseases. Handb Clin Neurol. 145, 301-307.
Lim, K, See, Y. M, & Lee, J. (2017). A systeatic review of the effectiveness of medical Cannabis for psychiatric, movement and neurodegenerative disorders. Clin Psychopharmacol Neurosci. 15(4), 301-312.
Maresova, P. et al. (2020). Activities of Daily Living and Associated Costs in the Most Widespread Neurodegenerative Diseases: A Systematic Review. Clin Interv Aging. 15, 1841-1862.
Matos, R. L. A. et al. (2017). Uso do canabidiol no tratamento da epilepsia. Rev Virl Química. 9(2), 786-814.
Nunes, K. M. S. et al. (2017). Canabidiol (Cannabis Sativa): associada no tratamento de doenças neurológicas e sua legalização. Revista Brasileira Militar de Ciências. 7, 14-21.
Patel, K. et al. (2021). Diabetic neuropathies. Muscle Nerve. 63(1), 22-30.
Ribeiro, J. A. C. (2014). A Cannabis e suas aplicações terapêuticas. Universidade Fernando Pessoa.
Rocha, F. L, Hara, C, & Paprocki, J. (2015). Doença mental e estigma. Rev Med Minas Gerais. 25(4).
Sales, J. A. et al. (2018). Antidepressant-like effect induced by Cannabidiol is dependente on brain serotonina levels. Prog. in Neuro Bio Psyc. 86, 255-261.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Jussara Fabiano de Oliveira; Any Gabrielly de Jesus Costa; Aida Carla Santana de Melo Costa; Licia Santos Santana; Davi Santana Sousa; Maria Jane das Virgens Aquino
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
